Small Cell Lung Cancer Pipeline 2024 | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio,

July 09 17:38 2024
Small Cell Lung Cancer Pipeline 2024 | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio,

DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Small Cell Lung Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Small Cell Lung Cancer Pipeline Outlook

 

Key Takeaways from the Small Cell Lung Cancer Pipeline Report

  • July 2024:- Merck Sharp & Dohme LLC- A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer. The goal of this study is to learn if people who receive vibostolimab and pembrolizumab live longer overall and without the cancer getting worse than people who receive pembrolizumab alone.
  • July 2024:- AbbVie- A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
  • DelveInsight’s Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
  • The leading Small Cell Lung Cancer Companies include Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
  • Promising Small Cell Lung Cancer Therapies in the various stages of development include Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.

 

Stay ahead with the most recent pipeline outlook for Small Cell Lung Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Small Cell Lung Cancer Approved Drugs

 

Small Cell Lung Cancer Emerging Drugs Profile 

  • AMG 757: Amgen

AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer. 

  • APG-1252: Ascentage Pharma

APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

 

Explore groundbreaking therapies and clinical trials in the Small Cell Lung Cancer Pipeline. Access DelveInsight’s detailed report now! @ Small Cell Lung Cancer Treatment Drugs

 

Small Cell Lung Cancer Companies

Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.

 

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Small Cell Lung Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Unveil the future of Small Cell Lung Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Small Cell Lung Cancer Market Drivers and Barriers

 

Scope of the Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Small Cell Lung Cancer Companies- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
  • Small Cell Lung Cancer Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.

 

Get the latest on Small Cell Lung Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Small Cell Lung Cancer Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Small Cell Lung Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Small Cell Lung Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Pembrolizumab: Merck & Co
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Dostarlimab: GlaxoSmithKline
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. AMG 757: Amgen
  17. Drug profiles in the detailed report…..
  18. Preclinical/Discovery Stage Products
  19. S 055746: Vernalis
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Small Cell Lung Cancer Key Companies
  23. Small Cell Lung Cancer Key Products
  24. Small Cell Lung Cancer- Unmet Needs
  25. Small Cell Lung Cancer- Market Drivers and Barriers
  26. Small Cell Lung Cancer- Future Perspectives and Conclusion
  27. Small Cell Lung Cancer Analyst Views
  28. Small Cell Lung Cancer Key Companies
  29. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/